香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 2024年第三季度報告； 戰略委員會及審計委員會工作細則修訂；及 戰略委員會更名 2024年第三季度報告 本部分公告乃上海昊海生物科技股份有限公司（「本公司」，連同其附屬公司統稱 「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09(2)及13.10B條以及 香港法例第571章證券及期貨條例第XIVA部刊發，旨在向本公司股東及公眾人士 提供本公司最新的財務資料。 茲載列本公司同時在上海證券交易所網站發佈的、截至2024年9月30日止三個月 及九個月之本集團未經審計業績（「第三季度報告」）。第三季度報告所載財務數據 乃根據中國企業會計準則編製，且未經審計。以下所載第三季度報告以中英文版 本編製。有任何歧 ...

Financial Performance - For the six months ended June 30, 2024, the company recorded revenue of approximately RMB 1,397.11 million, an increase of approximately RMB 91.40 million or 7.00% compared to RMB 1,305.71 million in the same period of 2023[9]. - Profit attributable to ordinary equity holders was approximately RMB 235.28 million, an increase of approximately RMB 30.04 million or 14.64% from RMB 205.24 million in the same period of 2023[9]. - Basic earnings per share for the period were RMB 1.01, compared to RMB 0.86 in the same period of 2023[9]. - The group reported a revenue of approximately RMB 1,397.11 million for the reporting period, an increase of RMB 91.40 million or 7.00% compared to RMB 1,305.71 million in the same period of 2023[38]. - Total comprehensive income for the six months ended June 30, 2024, was RMB 196,737,000, a decrease of 21.2% from RMB 249,563,000 in the same period of 2023[57]. - The profit attributable to equity holders of the parent company increased to RMB 235,283,000, up 14.6% from RMB 205,235,000 year-on-year[57]. - The group’s profit before tax for the six months ended June 30, 2024, was RMB 235,283,000, compared to RMB 205,235,000 for the same period in 2023, representing an increase of approximately 14.6%[84]. Revenue Breakdown - Revenue from the medical beauty and wound care product line was RMB 631.82 million, accounting for 45.22% of total revenue, with a year-on-year growth of 25.53%[11]. - Revenue from ophthalmic products was RMB 449.66 million, accounting for 32.18% of total revenue, showing a decline of 6.15% year-on-year[11]. - Revenue from orthopedic products was RMB 231.82 million, accounting for 16.59% of total revenue, with a slight increase of 0.28% year-on-year[11]. - Revenue from anti-adhesion and hemostatic products was RMB 68.87 million, accounting for 4.93% of total revenue, with a decline of 2.55% year-on-year[11]. - Revenue from the mainland China market was RMB 1,179,576 thousand, an increase of 11.3% from RMB 1,059,733 thousand in the previous year[71]. Research and Development - Research and development expenses for the period were approximately RMB 125.40 million, up by approximately RMB 24.01 million or 23.68% year-on-year, representing 8.98% of total revenue compared to 7.77% in 2023[9]. - The clinical trials for several key R&D projects progressed smoothly during the reporting period, including new high-oxygen contact lens products[12]. - The company continues to focus on the production and sales of bioproducts, medical-grade hyaluronic acid, and artificial lenses, with ongoing R&D in biotechnology and pharmaceuticals[70]. - Research and development costs increased to RMB 125,400,000 for the six months ended June 30, 2024, from RMB 101,391,000 in the same period of 2023, reflecting a growth of about 23.7%[78]. Dividends and Shareholder Returns - The board proposed an interim dividend of RMB 0.40 per share (tax included) for the six months ended June 30, 2024, compared to no dividend in the same period of 2023[9]. - The company proposed an interim dividend of RMB 0.40 per ordinary share, totaling RMB 93,192,000, compared to no dividend for the same period in 2023[82]. Market Position and Growth - The market share of the epidermal growth factor product "Kanghesu" was 26.91% in 2023, maintaining the second position in the domestic market[13]. - The company plans to expand the application of its epidermal growth factor product to multiple departments beyond traditional uses, enhancing its market reach[18]. - The Chinese medical aesthetics market is expected to grow by approximately 10% in 2024, with a compound annual growth rate of 10-15% over the next four years[17]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[154]. Cash Flow and Financial Position - Operating cash flow for the six months ended June 30, 2024, was RMB 380,712,000, an increase of 17.1% from RMB 325,038,000 in the same period of 2023[64]. - Cash and cash equivalents as of June 30, 2024, were approximately RMB 924.21 million, an increase of RMB 354.89 million from approximately RMB 569.32 million as of December 31, 2023[51]. - Total current assets as of June 30, 2024, were approximately RMB 3,720.36 million, a decrease of RMB 29.78 million or 0.79% from December 31, 2023[44]. - Total liabilities as of June 30, 2024, were approximately RMB 1,186.37 million, with a debt-to-asset ratio of 16.38%, an increase of 1.07 percentage points from 15.31% as of December 31, 2023[50]. Acquisitions and Investments - The company acquired 51% of Shanghai Shenhao Mijian Technology Development Co., Ltd. for a total consideration of RMB 36.2885 million, completed in June 2024[28]. - The cash outflow from investing activities related to the acquisition of Shenhao Mijian was RMB 16,009,000 after accounting for cash acquired[106]. Corporate Governance and Compliance - The interim financial report was approved by the board on August 16, 2024, and published on the Hong Kong Stock Exchange website[123]. - The company has complied with all applicable code provisions under the Corporate Governance Code during the reporting period[146]. - There were no significant legal proceedings or arbitrations involving the company during the reporting period[150]. Employee Compensation and Incentives - Employee compensation for the reporting period totaled approximately RMB 337.30 million, an increase of RMB 21.77 million from approximately RMB 315.53 million in the same period of 2023[46]. - The company has granted a total of 1,800,000 restricted shares under the 2021 A-share incentive plan, with the first vesting period completed[137]. - Total remuneration for key management personnel amounted to RMB 4,447,000 for the six months ended June 30, 2024, compared to RMB 3,471,000 for the same period in 2023, representing an increase of 28.1%[111].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 截至2024年6月30日止六個月期間之中期業績公告 截至2024年6月30日止六個月期間之中期業績摘要 • 報告期內，本集團共錄得營業收入約人民幣1,397.11百萬元（2023年同期：約 人民幣1,305.71百萬元），較2023年同期增加約人民幣91.40百萬元，增幅約 為7.00%。 • 報告期內，本集團研發開支約人民幣125.40百萬元，較2023年同期增加約人 民幣24.01百萬元，增幅約為23.68%，本集團研發開支佔收入比重為8.98% （2023年同期：7.77%）。 • 報告期內，本公司普通股權益持有人應佔利潤約為人民幣235.28百萬元（2023 年同期：約人民幣205.24百萬元），較20 ...

2024 年半年度报告 公司代码：688366 公司简称：昊海生科 上海昊海生物科技股份有限公司 2024 年半年度报告 1 / 188 2024 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 敬请参阅本报告"第三节 管理层讨论与分析"之"五、风险因素"相关内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人侯永泰、主管会计工作负责人唐敏捷及会计机构负责人（会计主管人员）卞亦平 声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司拟以实施权益分派股权登记日登记的总股本扣除公司回购专用证券账户中股份为基数， 向全体股东每10股派发现金红利人民币4.00元（含税）。截至本报告披露日，公司总股本235,489,895 股，扣除回购专用证券账户中股份数2,509,574股（其中包括2,015,674股A股股份，493,900股H股 股份），以此计算合计 ...

Financial Performance - The company's operating revenue for Q1 2024 was approximately RMB 645.99 million, representing a year-on-year increase of 5.68%[3] - Net profit attributable to shareholders for the same period was approximately RMB 97.54 million, reflecting a growth of 20.16% compared to the previous year[3] - The basic earnings per share for Q1 2024 was RMB 0.58, which is an increase of 23.40% year-on-year[3] - Net profit for Q1 2024 was RMB 92,488,777.12, up 9.0% from RMB 84,951,683.69 in Q1 2023[18] - Operating profit for Q1 2024 was RMB 114,427,839.61, slightly up from RMB 111,265,909.95 in Q1 2023[17] Research and Development - Research and development expenses totaled approximately RMB 64.90 million, accounting for 10.05% of operating revenue, which is an increase of 1.28 percentage points from the previous year[3] - Research and development expenses increased to RMB 64,900,123.30 in Q1 2024, representing a 21.1% rise from RMB 53,624,174.05 in Q1 2023[17] Cash Flow - The net cash flow from operating activities was approximately RMB 75.97 million, which decreased by 4.96% year-on-year[3] - Cash flow from operating activities for Q1 2024 was RMB 75,969,702.64, compared to RMB 79,930,962.49 in Q1 2023[21] - Cash flow from investing activities showed a net inflow of RMB 1,140,250,242.38 in Q1 2024, significantly higher than RMB 335,310,779.40 in Q1 2023[20] - Cash flow from financing activities resulted in a net inflow of RMB 42,137,675.19 in Q1 2024, compared to a net outflow of RMB 20,935,703.98 in Q1 2023[23] Assets and Liabilities - The total assets at the end of the reporting period were approximately RMB 7.19 billion, showing a slight increase of 1.23% from the end of the previous year[3] - The total assets as of March 31, 2024, amounted to CNY 7,192,952,822.94, an increase from CNY 7,105,496,951.15 as of December 31, 2023[12][16] - Current assets totaled CNY 3,745,333,949.09, slightly down from CNY 3,750,143,782.75 in the previous period[12] - Non-current assets increased to CNY 3,447,618,873.85 from CNY 3,355,353,168.40, indicating growth in long-term investments[13] - Total liabilities decreased to CNY 1,070,720,682.01 from CNY 1,088,203,977.97, reflecting improved financial stability[15] - The company's equity increased to CNY 6,122,232,140.93 from CNY 6,017,292,973.18, showing a positive trend in shareholder value[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,438[7] - The top shareholder, Jiang Wei, holds 28.17% of the shares, amounting to 47,520,000 shares[8] - The number of shares held by the top ten unrestricted shareholders reflects significant ownership concentration, with Jiang Wei holding 47,520,000 shares[10] Inventory and Receivables - Accounts receivable slightly increased to CNY 328,757,543.44 from CNY 327,861,290.31, suggesting stable revenue collection[12] - Inventory levels rose to CNY 533,642,335.66 from CNY 526,173,607.73, which may indicate preparation for increased sales[12] Other Financial Metrics - The company reported a decrease in other comprehensive income, with a net amount of RMB -21,216,593.79 in Q1 2024 compared to RMB 3,063,929.44 in Q1 2023[18] - Cash and cash equivalents were reported at CNY 2,677,447,776.76, down from CNY 2,740,678,648.51, indicating a reduction in liquidity[12]

Financial Performance - The company achieved a main business revenue of 2,645.07 million RMB in 2023, representing a growth of 25.11% compared to the previous year[6]. - The company's operating revenue for 2023 reached approximately CNY 2.65 billion, representing a 24.59% increase compared to CNY 2.13 billion in 2022[57]. - Net profit attributable to shareholders for 2023 was approximately CNY 416.12 million, a significant increase of 130.58% from CNY 180.47 million in 2022[57]. - The net profit attributable to shareholders of the listed company increased by 130.58% to 416.12 million yuan, while the net profit excluding non-recurring gains and losses rose by 141.52% to 383.41 million yuan[109]. - The net cash flow from operating activities increased by 174.30% to approximately CNY 634.45 million, driven by substantial growth in revenue and operating profit[59]. - The company's total assets at the end of 2023 were approximately CNY 7.11 billion, reflecting a 3.09% increase from CNY 6.89 billion at the end of 2022[57]. - The net assets attributable to shareholders increased by 2.46% to approximately CNY 5.65 billion at the end of 2023[57]. - The company's basic earnings per share increased by 134.62% to CNY 2.44 in 2023, compared to CNY 1.04 in 2022[85]. Research and Development - The company has invested a total of 7,033.32 million RMB in various R&D projects, with a cumulative investment of 25,963.14 million RMB[11]. - The R&D team consists of 366 personnel, accounting for 16.96% of the total workforce, with an average salary of 33.04 thousand yuan[18]. - The company has established multiple R&D platforms, including a national-level enterprise technology center and a national postdoctoral research station, enhancing its research capabilities[21]. - Research and development expenses amounted to CNY 220,098,300, representing a 20.81% increase from the previous year, accounting for 8.29% of total revenue[82]. - The company is actively increasing R&D investment to develop new technologies and products, focusing on core technology transformation[184]. Product Development and Innovation - The company is conducting clinical trials for several new products, including a new type of artificial lens and a high-permeability scleral lens, with expected product approvals in early 2024[11]. - The company is developing innovative products such as a new type of cross-linked chitosan gel and a long-acting cross-linked sodium hyaluronate injection, which are expected to enhance treatment efficacy[11]. - The company successfully launched a new hydrophobic aspheric intraocular lens product in June 2023, with several other innovative products in various stages of clinical trials[82]. - The company has developed a second-generation PRL product for myopia correction, with clinical trials progressing smoothly, and high-permeability scleral lenses expected to complete registration testing by February 2024[157]. - The company has developed a large-scale sodium hyaluronate injection product that is now in the clinical application stage[191]. Market Expansion and Strategy - The company has expanded its international presence through acquisitions, focusing on transferring advanced technologies and products to the domestic market[1]. - The company plans to continue its market expansion and product development strategies, focusing on high-margin products like hyaluronic acid[3]. - The company aims to enhance the brand image of its high-end hyaluronic acid product "Haimi" and expand market penetration in 2024[127]. - The company is focusing on expanding its product matrix across four major categories: hyaluronic acid, epidermal repair gene engineering preparations, RF, and laser equipment, catering to diverse consumer needs in medical and home beauty applications[160]. - The company plans to focus on the ophthalmology sector in 2024, adapting to changes in industry policies and leveraging its multi-brand product line advantages[126]. Operational Efficiency and Cost Management - The company has reduced cash outflow from investment activities due to effective cash management, particularly in the purchase of bank certificates[5]. - The company emphasized the importance of cash flow management, noting efforts to reduce accounts receivable and enhance collection efforts[59]. - The company has established a procurement center to enhance operational efficiency and reduce costs through centralized purchasing of raw materials and equipment[178]. - The company is actively monitoring overdue accounts receivable and has reduced or stopped credit sales to clients with credit risks, leading to a decrease in accounts receivable balance[4]. Market Position and Brand Influence - The company's ophthalmic viscoelastic product has maintained a market share of 16 consecutive years as the leading product in the domestic market[16]. - The company has a leading brand influence in various treatment areas, with its products ranking among the top in sales within their respective categories[27]. - The company is the only domestic manufacturer with a full range of orthopedic sodium hyaluronate injection products in 2ml, 2.5ml, and 3ml specifications[17]. - The company holds a 46.45% market share in the orthopedic joint cavity viscoelastic supplement market in China, maintaining the leading position for nine consecutive years[172]. - The company is the largest producer of surgical anti-adhesion agents in China, with a market share of 29.90% in 2022, also maintaining this position for 16 years[183]. Challenges and Future Outlook - The company has not yet achieved profitability since its listing, as indicated in the report[44]. - The management highlighted future growth strategies, although specific commitments were not made to investors[60]. - The group plans to advance the registration of several key products in 2024, including hydrophobic aspheric multifocal intraocular lenses and innovative intraocular filling biological gel products[142]. - The group aims to enhance its operational efficiency and core competitiveness through the integration of acquired companies and resource allocation in 2024[153]. - The Chinese medical aesthetics market is projected to grow at a compound annual growth rate of 15%-20% over the next five years, driven by increasing consumer demand and a low penetration rate compared to other countries[132].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 645,995,271.22, representing a year-on-year increase of 5.68%[6] - The net profit attributable to shareholders for Q1 2024 was CNY 97,541,532.98, reflecting a growth of 20.16% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 95,217,851.02, which is an increase of 33.05% year-on-year[6] - The basic earnings per share for Q1 2024 was CNY 0.58, up by 23.40% from CNY 0.47 in Q1 2023[18] - Net profit for the current period reached 92,488,777.12, an increase from 84,951,683.69 in the previous period, representing a growth of approximately 6.4%[41] - Total revenue from operating profit was 114,427,839.61, slightly up from 111,265,909.95, indicating a growth of about 1.9%[41] - The company's earnings per share attributable to shareholders increased to 97,541,532.98 from 81,177,581.15, representing a growth of about 20.2%[41] Assets and Liabilities - The total assets at the end of Q1 2024 amounted to CNY 7,192,952,822.94, a 1.23% increase from the end of the previous year[26] - As of March 31, 2024, total current assets amounted to approximately RMB 3.75 billion, slightly down from RMB 3.75 billion at the end of 2023[32] - The company’s total assets reached approximately RMB 7.19 billion, up from RMB 7.11 billion at the end of 2023[32] - The company's total liabilities amounted to 1,070,720,682.01, a decrease from 1,088,203,977.97, reflecting a reduction of approximately 1.6%[45] - The total equity attributable to shareholders increased to 5,755,069,480.72 from 5,650,064,203.23, marking an increase of about 1.9%[45] Cash Flow - The net cash flow from operating activities for Q1 2024 was CNY 75,969,702.64, a decrease of 4.96% compared to the previous year[6] - The company reported a net cash inflow from investment activities of CNY 159,290,447.77 for Q1 2024, compared to CNY 156,184,009.96 in the same period last year[19] - The company reported a net cash inflow from financing activities of approximately RMB 42.14 million, a significant improvement from a net outflow of RMB 20.94 million in the previous period[38] Research and Development - The total R&D expenditure for Q1 2024 was CNY 64,900,123.30, which accounted for 10.05% of the operating revenue, an increase of 1.28 percentage points year-on-year[26] Shareholder Information - The top ten shareholders hold a combined 88.68% of the shares, with the largest shareholder owning 28.17%[28] Government Subsidies - The company received government subsidies amounting to CNY 3,820,341.64 during the reporting period[26] - Government subsidies received during the reporting period decreased significantly compared to the same period last year, leading to a 75.83% decline in non-recurring net gains[28] Inventory and Cash Management - Cash and cash equivalents at the end of the reporting period were RMB 846.19 million, an increase from RMB 772.22 million at the end of the previous year[38] - Inventory as of March 31, 2024, was approximately RMB 533.64 million, showing a slight increase from RMB 526.17 million at the end of 2023[32] Strategic Focus - The company continues to focus on high-margin hyaluronic acid products, contributing to overall gross profit growth[28] - The company is actively exploring new product development and market expansion strategies to enhance its competitive position[28] Other Financial Metrics - The weighted average return on equity for Q1 2024 was 1.72%, an increase of 0.24 percentage points year-on-year[26] - Interest income decreased to 17,894,671.58 from 19,194,643.89, a decline of approximately 6.8%[41] - Other comprehensive income after tax showed a significant drop to -21,216,593.79 from 3,063,929.44, indicating a negative shift[41] - The company reported a decrease in credit impairment losses to -476,413.55 from -2,445,931.34, showing an improvement in credit quality[41] - The company’s capital reserve decreased to 2,903,610,489.65 from 2,980,937,753.79, a decline of approximately 2.6%[45]

Financial Performance - Total revenue for 2023 reached RMB 2,634,910,000, an increase of 25.2% compared to RMB 2,103,438,000 in 2022[6] - Net profit attributable to shareholders was RMB 416,121,000, up 130.5% from RMB 180,470,000 in the previous year[6] - Earnings per share increased to RMB 2.44 in 2023, compared to RMB 1.04 in 2022[6] - The company achieved a total revenue of RMB 2,634.91 million in 2023, representing a year-on-year increase of 25.27%[7] - The company’s net profit attributable to ordinary shareholders was approximately RMB 416.12 million, an increase of about RMB 235.65 million or 130.58% from RMB 180.47 million in 2022[42] - The overall gross margin for the company was 70.34% in 2023, up from 68.79% in 2022, primarily due to strong sales performance of high-margin hyaluronic acid products[37] Assets and Liabilities - Total assets as of December 31, 2023, amounted to RMB 7,105,497,000, a rise from RMB 6,892,399,000 in 2022[6] - Total liabilities increased to RMB 1,088,204,000 from RMB 990,016,000 in 2022, resulting in a debt-to-asset ratio of 15.3%[6] - Total current liabilities of the group as of December 31, 2023, were approximately RMB 715.95 million, an increase of about RMB 204.67 million or 40.03% compared to December 31, 2022[43] - The total liabilities of the group as of December 31, 2023, were approximately RMB 1,088.20 million, with a debt-to-asset ratio of 15.31%, an increase of 0.95 percentage points from 14.36% as of December 31, 2022[48] Research and Development - Research and development efforts are focused on innovative technologies to enhance product offerings and competitiveness[6] - Research and development expenses amounted to RMB 220.10 million, an increase of 20.81% year-on-year, accounting for 8.35% of total revenue[11] - The company is actively developing innovative high-end artificial lens products, with several clinical trials underway for new technologies[18] - The company is focusing on expanding its product lines in ophthalmology and medical aesthetics, with several innovative products entering the registration phase[11] Market Expansion and Strategy - The company plans to expand its market presence and invest in new product development to drive future growth[6] - Management remains optimistic about future performance, expecting continued revenue growth and improved profitability[6] - The company is exploring potential mergers and acquisitions to accelerate growth and market expansion[6] - The company aims to expand its market share in the medical aesthetics sector by promoting its differentiated hyaluronic acid products through a broad sales network in 2024[36] Product Performance - The ophthalmic product line generated revenue of RMB 924.65 million, accounting for 35.10% of total revenue, with a growth rate of 20.72%[10] - The medical beauty and wound care product line saw revenue of RMB 1,052.80 million, representing 39.95% of total revenue, with a year-on-year growth of 41.44%[10] - The company's hyaluronic acid product line includes three generations, with the first generation achieving sales of RMB 599.41 million, accounting for 56.94% of total revenue in 2023, reflecting a growth of 95.78% year-on-year[23] - The company's ophthalmic products achieved revenue of RMB 924.65 million, an increase of approximately RMB 158.68 million, representing a growth rate of 20.72% compared to the previous year[14] Shareholder Returns - The board proposed a final dividend of RMB 1.00 per share for the year 2023, reflecting a 150% increase compared to the previous year[7] - The company plans to distribute a final dividend of RMB 1.00 per share for the year ending December 31, 2023, totaling RMB 167,360,375.00[58] - The company’s profit distribution policy emphasizes a stable and sustainable return to investors, with cash dividends prioritized when conditions allow[64] Corporate Governance - The company has established a corporate governance structure to protect shareholder rights and enhance accountability[123] - The company has adhered to all applicable provisions of the corporate governance code during the reporting period[117] - The board consists of 11 members, including 4 executive directors, 2 non-executive directors, and 5 independent non-executive directors[123] - The company has established internal policies to ensure the board receives independent views and opinions, with independent non-executive directors entitled to seek independent professional advice at the company's expense[127] Risk Management - The company has established a stable and effective risk management mechanism, including an internal audit system and risk assessment management system[183] - The company faces potential risks from intensified market competition, which could impact its market share and profitability[157] - Regulatory changes in China's healthcare system may increase compliance costs and reduce product demand if the company fails to adapt[158] Employee and Management - The total employee compensation for the group during the reporting period was approximately RMB 630.08 million, with a total workforce of 2,158 employees[44] - The company has implemented a restricted stock incentive plan approved on March 7, 2022, to attract and retain core management and technical personnel, with a total of 1,800,000 shares granted under this plan[91] - The company has arranged appropriate liability insurance for its directors, supervisors, and senior management[84] Community and Social Responsibility - The company made donations amounting to RMB 100,000 during the reporting period[119] - Community engagement includes donations, public welfare activities, and industry meetings[200] Compliance and Legal Matters - The company has not encountered any corruption or bribery lawsuits during the reporting period, reflecting its commitment to integrity and compliance[186] - The company has complied with all disclosure requirements under Chapter 14A of the Hong Kong Listing Rules regarding related party transactions[116]

识别风险，发现价值 请务必阅读末页的免责声明 1 / 4 [Table_PageText] 昊海生科|年报点评 [Table_FinanceDetail] 资产负债表 单位：百万元 现金流量表 单位：百万元 至 12 月 31 日 2022A 2023A 2024E 2025E 2026E 至 12 月 31 日 2022A 2023A 2024E 2025E 2026E 流动资产 3,532 3,750 4,079 4,878 5,799 经营活动现金流 231 634 214 1,322 1,011 货币资金 2,545 2,741 2,372 3,170 3,747 净利润 190 412 558 758 908 应收及预付 440 380 940 804 960 折旧摊销 204 198 178 195 205 存货 485 526 675 791 958 营运资金变动 -138 90 -658 362 -177 其他流动资产 62 103 92 112 134 其它 -26 -66 136 7 74 非流动资产 3,360 3,355 3,398 3,569 3,569 投资活动现金流 -682 - ...

[Table_Main] 证券研究报告 | 公司点评 昊海生科(688366.SH) 2024 年 03 月 10 日 增持（维持） 所属行业：医药生物/医疗器械 当前价格(元)：104.22 证券分析师 赵雅楠 资格编号：S0120523070002 邮箱：zhaoyn＠tebon.com.cn 易丁依 资格编号：S0120523070004 邮箱：yidy＠tebon.com.cn 市场表现 -17% -9% 0% 9% 17% 26% 昊海生科 沪深300 -26% | --- | --- | --- | --- | |--------------------------------|----------------|--------------|-------| | -34% 2023-03 \n沪深 300 对比 | 2023-07 \n1M | 2023-11 \n2M | 3M | | 绝对涨幅 (%) | -3.50 | 3.87 | -3.10 | | 相对涨幅 (%) | -8.85 | -3.80 | -7.37 | | 资料来源：德邦研究所，聚源数据 | | | | 相关研究 1.《昊 ...